Caption Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-28,341
Closed -$1.38M 2047
2025
Q3
$1.35M Buy
+28,341
New +$1.14M 0.01% 998
2021
Q4
Sell
-12,000
Closed -$320K 1919
2021
Q3
$320K Buy
+12,000
New +$322K ﹤0.01% 1284
2021
Q1
Sell
-58,000
Closed -$1.46M 1382
2020
Q4
$1.46M Buy
+58,000
New +$1.25M 0.03% 525
2019
Q2
Sell
-19,400
Closed -$681K 817
2019
Q1
$681K Sell
19,400
-19,600
-50% -$729K 0.04% 415
2018
Q4
$1.3M Buy
+39,000
New +$1.68M 0.1% 237

Other funds holding SUPN

Caption Management's SUPN Position: Q4 2025 in Review

Caption Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 28,341 shares — an estimated $1.38M sold.

Caption Management first reported a position in SUPN in Q4 2018 and held it in 5 quarters. The position peaked at $1.46M in Q4 2020. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Caption Management reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 28,341 Supernus Pharmaceuticals shares in Q4 2025, an estimated $1.38M.
  • Caption Management first reported a position in Supernus Pharmaceuticals in Q4 2018 and held it in 5 quarters.
  • Caption Management's Supernus Pharmaceuticals position peaked at $1.46M in Q4 2020.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.